Last reviewed · How we verify
Metarsen (oxophenarsine)
Metarsen (generic name: oxophenarsine) is a oxophenarsine drug. It is currently in unknown development.
Metarsen works by interfering with the production of nucleic acids in cells.
Metarsen (oxophenarsine) is a small molecule drug in the oxophenarsine class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or off-patent. The approved indications for Metarsen are also unknown. As a result, its commercial status, half-life, bioavailability, and generic manufacturers are also unclear. Further research is needed to understand the safety and efficacy of Metarsen.
At a glance
| Generic name | oxophenarsine |
|---|---|
| Drug class | oxophenarsine |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of it like a puzzle: Metarsen disrupts the process of building the instructions that cells use to grow and multiply. This can help slow down the growth of certain cells, which can be beneficial in treating diseases. However, it's a complex process, and more research is needed to fully understand how it works.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metarsen CI brief — competitive landscape report
- Metarsen updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Metarsen
What is Metarsen?
How does Metarsen work?
What is the generic name of Metarsen?
What drug class is Metarsen in?
What development phase is Metarsen in?
Related
- Drug class: All oxophenarsine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing